OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Average Recommendation of “Hold” from Analysts

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) has earned a consensus rating of “Hold” from the five ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $6.3333.

A number of equities research analysts have recently commented on OKYO shares. Piper Sandler started coverage on OKYO Pharma in a research report on Friday, February 20th. They set an “overweight” rating and a $7.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of OKYO Pharma in a research report on Tuesday, April 21st.

OKYO Pharma Trading Up 1.2%

Shares of NASDAQ:OKYO opened at $1.68 on Friday. OKYO Pharma has a one year low of $1.44 and a one year high of $3.35. The stock has a fifty day moving average of $1.62 and a 200-day moving average of $1.85.

Institutional Trading of OKYO Pharma

A number of hedge funds have recently modified their holdings of the business. XTX Topco Ltd purchased a new stake in shares of OKYO Pharma in the fourth quarter valued at $36,000. Renaissance Technologies LLC lifted its holdings in shares of OKYO Pharma by 235.0% in the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock valued at $286,000 after purchasing an additional 96,800 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new stake in shares of OKYO Pharma in the third quarter valued at $31,000. Hedge funds and other institutional investors own 2.97% of the company’s stock.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.